{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-022648","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2024-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.238611+00:00","generated_at":"2026-06-06T02:28:31.430135+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NRx receives $5M advance milestone from Alvogen/Lotus, issues 4.2M warrants at $0.40","bullets":["$5M received immediately; funds NRX-101 development through Phase 2 FDA meeting.","Alvogen receives 4,195,978 warrants at $0.40 strike, 3-year term.","Second $4M milestone due within 60 days of positive end-of-Phase 2 FDA meeting.","NRx eligible for up to $320M in future milestones and tiered double-digit royalties.","Alvogen/Lotus to cover future NRX-101 development and commercialization costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-022648","json":"https://secwatch.observer/filing/0001104659-24-022648.json","markdown":"https://secwatch.observer/filing/0001104659-24-022648.md","text":"https://secwatch.observer/filing/0001104659-24-022648.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000110465924022648/0001104659-24-022648-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000110465924022648/tm246184d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T02:28:31.430135+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8931fbf04da8c22dcdb8b3d77cb554939ef6c040","claim":"NRX Pharmaceuticals, Inc. amended First Amendment with Alvogen Pharma US, Inc., Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. valued at $5 million (effective 2024-02-07).","evidence_excerpt":"On February 7, 2024, NeuroRx, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (together, the “ Company ”), entered into the First Amendment (the “ Amendment ”) to the Exclusive, Global Development, Supply, Marketing & License Agreement, dated as of June 2, 2023 (the “ License Agreement ”), with Alvogen Pharma US, Inc., Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. (collectively, “ Alvogen ”), effective as of the same date.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000110465924022648/0001104659-24-022648-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Alvogen Pharma US, Inc., Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd."},{"label":"Value","value":"$5 million"},{"label":"Effective","value":"2024-02-07"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}